Panadea Diagnostics Gmbh

What Panadea Diagnostics Gmbh does

Panadea Diagnostics GmbH is a Hamburg, Germany-based biotechnology company founded in March 2023 by three scientists — Dr. Yang Liu (CEO), Ben Rushton (COO), and Dr. Christina Deschermeier (CSO) — to develop and commercialize serological ELISA test kits for the research and surveillance of tropical and emerging infectious diseases on the WHO Blueprint List of Priority Diseases. The company's core technology is a patented membrane Fc-receptor-based immune complex capture ELISA platform, supplemented by a proprietary Specificity Enhancer chemistry that suppresses cross-reactive interference from co-circulating flaviviruses; together these enable IgG and IgM antibody detection against pathogens including CCHFV, ZIKV, LASV, Ebola, Marburg, Sudan, Dengue, West-Nile, RVFV, and SARS-CoV-2. The portfolio comprises 23 Research Use Only kits in 96-well format, originating from the BLACKBOX ELISA line developed at the Bernhard-Nocht Institute for Tropical Medicine (BNITM) and transferred to Panadea at founding. The company sells directly to research laboratories and health authorities worldwide through its website, with products currently used in over 20 countries, and maintains a continuing co-development and validation relationship with BNITM, an additional co-development partnership with the Kumasi Center for Collaborative Research (KCCR) in Ghana, and a Global Health Education Grant program with iACE Global Health to train LMIC laboratory professionals. The business model is one-time RUO reagent sales with non-publicly-disclosed pricing and no disclosed external funding to date; revenue figures are not publicly available.

Name

Panadea Diagnostics Gmbh

Legal name

Panadea Diagnostics GmbH

Website

https://panadea-diagnostics.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Panadea Diagnostics GmbH is a Hamburg-based biotech that develops and sells patented, Research Use Only ELISA kits for the surveillance of WHO Blueprint priority tropical and emerging infectious diseases, serving researchers, health authorities, and LMIC laboratories across more than 20 countries.

Ownership category

akta.pro rank

Product category

Infectious Disease Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Immunoassay Diagnostics (ELISA, chemiluminescence, serology) (HLAAALAB)

akta.pro secondary industries

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)

Keywords

• Serological ELISA kits
• Infectious disease diagnostics
• Tropical disease research
• Research use only assays
• Antigen detection kits

Headquarters

HQ city

Hamburg

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. ELISA Kit Sales: Sale of Research Use Only ELISA test kits for detection of antibodies against tropical and emerging infectious diseases including CCHFV, ZIKV, LASV, Ebola, Marburg, Sudan, Dengue, West-Nile, SARS-CoV-2, and RVFV viruses.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Panadea Diagnostics develops, manufactures, and sells Research Use Only (RUO) serological ELISA test kits for the detection of IgG and IgM antibodies against tropical and emerging infectious diseases on the WHO Blueprint List of Priority Diseases, including CCHFV, ZIKV, LASV, Ebola, Marburg, Sudan, Dengue, West-Nile, SARS-CoV-2, and RVFV. The kits are based on a patented membrane Fc-receptor-based immune complex capture assay platform, are produced in 96-well format, and are sold directly to research laboratories, scientists, and public health authorities worldwide.

Product overview

Panadea Diagnostics GmbH is a Germany-based biotechnology company offering a portfolio of specialist immune capture ELISA test kits for tropical and emerging infectious diseases. The product line comprises 23 Research Use Only (RUO) serological ELISA kits targeting diseases on the WHO Blueprint List of Priority Diseases, including filoviruses (Ebola, Marburg, Sudan), flaviviruses (Dengue, Zika, West-Nile), and other priority pathogens (CCHFV, LASV, RVFV, SARS-CoV-2). The core technology is a patented membrane receptor-based immune complex capture assay platform, with some variants incorporating a proprietary Specificity Enhancer (SE) technology to suppress cross-reactive interference. Kits are formatted as 96-well test plates and detect either IgG or IgM antibodies in human serum/plasma samples. The company was previously known as BLACKBOX, with its ELISA kits rebranded to Panadea in March 2023.

Differentiator

Problem solved

Functional benefit

Products and services

• Crimean-Congo Hemorrhagic Fever Virus (CCHFV) ELISA Kits Qualitative Research Use Only ELISA kits for the detection of human IgG and IgM antibodies against the Crimean-Congo Hemorrhagic Fever Virus nucleocapsid protein (NP) in serum or plasma, in 96-well format, based on the patented immune complex capture principle. Targeted at researchers and public health laboratories working on this WHO Blueprint priority pathogen.
• Lassa Virus (LASV) ELISA Kits Qualitative Research Use Only ELISA kits for the detection of human IgG and IgM antibodies against the Lassa Virus nucleocapsid protein (NP) in serum or plasma, in 96-well format, based on the patented immune complex capture principle (IgG) or µ-capture assay principle (IgM). Targeted at researchers and public health laboratories working on this WHO Blueprint priority pathogen.
• Filovirus IgG ELISA Kits (Ebola, Marburg, Sudan) Research Use Only qualitative ELISA kits for the detection of human IgG antibodies against Ebola, Marburg, and Sudan virus nucleoproteins (NP) in serum or plasma, in 96-well format, using the patented membrane Fc-receptor immune complex capture principle. Targeted at filovirus researchers, outbreak response laboratories, and public health surveillance programs.
• Dengue Virus (DENV) ELISA Kits Research Use Only ELISA kits for the detection of human IgG and IgM antibodies against Dengue virus (serotypes 1-4) nonstructural protein 1 (NS1) in serum or plasma, in 96-well format, based on the patented immune complex capture principle with optional proprietary Specificity Enhancer (SE) for suppression of cross-reactivities from other flavivirus infections. Targeted at flavivirus researchers and surveillance laboratories in endemic regions.
• Zika Virus (ZIKV) ELISA Kits Research Use Only ELISA kits for the detection of human IgG and IgM antibodies against Zika Virus NS1 and envelope protein domain III (EDIII) antigens in serum or plasma, in 96-well format, based on the patented immune complex capture principle with proprietary Specificity Enhancer (SE) variants available for cross-reactivity suppression. Targeted at flavivirus researchers and surveillance laboratories in endemic regions.
• West-Nile Virus (WNV) ELISA Kits Research Use Only ELISA kits for the detection of human IgG antibodies against West-Nile Virus lineage 1 and lineage 2 NS1 antigens in serum or plasma, in 96-well format, based on the patented immune complex capture principle with proprietary Specificity Enhancer (SE) variants available for cross-reactivity suppression. A combo kit detects antibodies against both lineages simultaneously. Targeted at flavivirus researchers and surveillance laboratories in endemic regions.
• SARS-CoV-2 ELISA Kits Research Use Only qualitative ELISA kits for the detection of human IgG and IgM antibodies against SARS-CoV-2 nucleocapsid protein (NP) in serum or plasma, in 96-well format, including an IgG Plus variant optimised for detection of low antibody levels. Based on the patented immune complex capture principle and targeted at COVID-19 seroprevalence and immunology researchers.
• Rift Valley Fever Virus (RVFV) IgG ELISA Kit Qualitative Research Use Only ELISA kit (ELG.012) for the detection of human IgG antibodies against Rift Valley Fever Virus nucleoprotein (NP) in serum or plasma, in 96-well format, based on the patented immune complex capture principle. Targeted at researchers and surveillance programs working on this WHO Blueprint priority pathogen.

Quantifiable outcome

• High sensitivity and specificity proven in comparative studies and population seroprevalence studies
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core, flagship and minor.

• Bernhard Nocht Institute for Tropical Medicine (BNITM)coreStrategic or Co-development Partner · 29 March 2023Transfer of BLACKBOX ELISA kits from BNITM to Panadea Diagnostics. The kits were developed at BNITM and have been highly sought after in relevant research fields. Products covering Zika, Crimean Congo Hemorrhagic Fever, SARS-CoV-2, and Lassa Fever viruses were transferred to secure the delivery chain.
• Bernhard Nocht Institute for Tropical Medicine (BNITM)coreStrategic or Co-development PartnerLong-term partnership for innovations and technical solutions. BLACKBOX ELISA kits were developed at BNITM and transferred to Panadea. Products validated in cooperation with BNITM. BNITM is internationally recognized for tropical and emerging infectious diseases research, combining research, clinical expertise, and public health approaches. BNITM is also home to iACE Global Health training programs.
• Kumasi Center for Collaborative Research (KCCR)coreStrategic or Co-development PartnerCollaboration with scientists at KCCR in Ghana for pre-release testing of Marburg IgG ELISA Kit. KCCR provided valuable feedback and validation, reporting excellent results with the kit in their research on filoviruses.
• iACE Global HealthflagshipStrategic or Co-development PartnerCollaboration through Panadea Global Health Education Grant. iACE Global Health at BNITM offers two flagship training programs: EPICID (Epidemiology & Control of Infectious Diseases in Outbreak Settings) and LAB-SPHERE (Laboratory Systems and Public Health in Resource-Limited Settings). iACE conducts application processing and candidate selection for the grant.
• Altona Diagnostics GmbHminorOthersDr. Markus Hess from Altona Diagnostics GmbH serves on Panadea's Scientific Advisory Board on a voluntary, unpaid basis. Altona Diagnostics is also based in Hamburg, Germany. Advisory board members evaluate Panadea's scientific quality and direction.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• EUROIMMUN (PerkinElmer): EUROIMMUN is the leading European manufacturer of infectious disease ELISA kits, with broad menus covering flaviviruses, filoviruses, and other tropical pathogens. It is the most direct commercial competitor to Panadea in the serological ELISA space, though it operates at much larger scale with IVD-certified products and global distribution.
• Creative Diagnostics: US-based manufacturer of ELISA kits and diagnostic reagents with a catalog spanning infectious diseases, including tropical and emerging pathogens. Comparable to Panadea in product format (RUO ELISA kits) and direct-to-customer online sales motion, though with a broader and more generic catalog.
• InBios International: US-based developer of immunodiagnostics for emerging infectious diseases, with ELISA and rapid test products targeting flaviviruses, filoviruses, and other tropical pathogens. Directly comparable to Panadea in disease focus and customer base (research labs, surveillance programs, public health agencies).
• Vircell S.L. Spanish developer and manufacturer of ELISA kits and other infectious disease diagnostics targeting similar pathogens to Panadea. Overlaps directly on flavivirus and other tropical disease serology products and shares a similar European SME profile with a research-focused customer base.
• Reagena Oy: Finnish diagnostics company specializing in lateral flow and ELISA products for tropical and emerging infectious diseases. Highly comparable to Panadea as a niche European SME focused on the same WHO Blueprint priority pathogen set, with similar RUO/IVD product positioning.
• Dia.Pro Diagnostic Bioprobes: Italian-based ELISA kit manufacturer with a broad infectious disease menu including tropical and emerging pathogens. Comparable to Panadea in product format (RUO and IVD ELISA kits) and customer base (clinical labs, research institutions), but with significantly more SKUs and a longer commercial track record.
• NovaTec Immundiagnostica (NovaLisa): Germany-based manufacturer of ELISA test kits (branded NovaLisa) for infectious disease serology, including tropical pathogens. Directly comparable in technology, geography, RUO/IVD positioning, and customer base to Panadea, with overlapping product lines on flaviviruses and similar pathogens.

Broad incumbents

• IBL International (Tecan): Specialty ELISA and immunoassay kit manufacturer within Tecan's diagnostics portfolio, offering infectious disease and endocrine ELISA products. Comparable in technology platform and customer base to Panadea, but with broader menus, established IVD certifications, and integration into Tecan's automated immunoassay platforms.
• Abcam: Global life science tools leader supplying antibodies, ELISA kits, and reagents to research laboratories worldwide. Comparable to Panadea as a research-use reagent supplier with overlapping ELISA kit offerings, but operating at vastly larger scale with a catalog spanning thousands of targets rather than a focused tropical disease menu.

Regional players

• Altona Diagnostics GmbH: Hamburg-based molecular diagnostics company whose Scientific Advisory Board member (Dr. Markus Hess) advises Panadea. While primarily a molecular (PCR) diagnostics player rather than ELISA, it is geographically co-located and operates in the same Hamburg infectious disease diagnostics ecosystem serving similar end-customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/panadea-diagnostics-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Panadea Diagnostics Gmbh